Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02629926
Other study ID # ED07/8440
Secondary ID
Status Recruiting
Phase Phase 4
First received February 9, 2015
Last updated December 14, 2015
Start date October 2010

Study information

Verified date December 2015
Source The Leeds Teaching Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority Health Research Authority:UK
Study type Observational

Clinical Trial Summary

Cure rates for childhood malignancies have improved at a remarkable pace.With the increasing cure rate came recognition of the long-term detrimental effects of radiotherapy and chemotherapy, known as "late-effects". Endocrine late-effects are particularly prevalent in childhood cancer survivors. Growth Hormone (GH) deficiency is common following radiation to the head and leads to impaired growth, hence GH replacement is given to achieve optimise final height in childhood. In the adult GH is important to maintenance of bone, muscle & fat mass; vascular risk factors; and quality of life. This observational study aims to determine the long-term effect of low dose GH replacement on development of bone, muscle and fat mass; vascular risk; and quality of life in the early years after achievement of final height, a time known as "transition". GH is thought to be essential to development of bone, muscle, and fat mass during this time period.

Patients will be identified in the late -effects endocrine clinic, aged 16-22yrs, who are severely GH deficient. 30 patients will be recruited to the study who wish to continue receiving GH replacement, all of whom will receive recombinant GH. An additional 30 patients who do not wish to receive GH replacement will provide a parallel control data.

All patients will undergo baseline assessment including examination; routine blood tests; urine dipstick; measures on height, weight, waist, and 24 hour blood pressure. Measures will be repeated at six months, and then annually until 25 years of age. Bone density will be measured at baseline, after two years and at age 25yrs. Patients requesting GH replacement will require initial additional visits to teach self injection, then 2-4wkly to assess when correct dose of GH is achieved. The study will enable assessment of the beneficial effects of GH replacement during transition in GH deficient survivors of cancer to be realised.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 22 Years
Eligibility Inclusion Criteria:

- Aged 16--22 years inclusive.

- Both genders.

- Able to provide informed consent.

- Severe GH deficiency (peak GH<5mcg/l on stimulation).

- No GH replacement therapy during the three months preceding the baseline visit.

- Stable anterior pituitary hormone (i.e. sex steroids, hydrocortisone, thyroxine) therapy over the previous six months.

- Life expectancy >24 months.

Exclusion Criteria:

- Acute critical illness (Patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure, or similar conditions).

- Active malignant disease (i.e. undergoing active treatment or palliation).

- Patients treated for an intracranial malignancy should have completed therapy two years prior to entering the study.

- Active Cushing's disese or acromegaly

- Pregnancy or desire to conceive within the following year. Patients at risk of pregnancy will be screened by urine pregnancy (HCG) test at the baseline evaluation & treatment initiation visit.

- Breast feeding.

- Proliferative diabetic retinopathy.

- Sensitivity to GH or its preservative

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
GH Replacement (NutropinAq®)
GH Replacement continued.
No additional treatment
GH Replacement not continued.

Locations

Country Name City State
United Kingdom The Leeds Teaching Hospitals NHS Trust Leeds

Sponsors (1)

Lead Sponsor Collaborator
The Leeds Teaching Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare the change in quality of life (QoL) at twelve months with that at baseline for the two treatment groups. For the primary endpoint this will be determined using the GH -specific instrument, the Adult Growth 12 monthly intervals until the age of 25yrs No
Secondary compare the change in QoL at each assessment timepoint versus to Baseline for the two treatment groups three generic selfrating questionnaires 12 monthly intervals until the age of 25yrs No
Secondary Psychological General WellBeing Schedule (PGWBS) Questionnaire completed at 12 months 12 monthly intervals until the age of 25yrs No
Secondary Shortform 36 (SF36) questionnaire Questionnaire completed at 12 months 12 monthly intervals until the age of 25yrs No
Secondary EuroQoL 5D (EQ5D) questionnaire AGHDA SF36 PGWBS EQ5D 12 monthly intervals until the age of 25yrs No
Secondary compare the change in body composition between the two treatment groups at each assessment timepoint versus Baseline. Weight Height Waist & hip circumference Skin thickness Bioimpedance Total body DXA scan 12 monthly intervals until the age of 25yrs No
Secondary compare the change in cardiovascular risk factors between the two treatment groups at each assessment every 12 months versus Baseline. 12 monthly intervals until the age of 25yrs No
Secondary compare the change in bone mineral content between the two treatment groups at each assessment every 12 months versus Baseline. 12 monthly intervals until the age of 25yrs No
Secondary compare the change in bone turnover between the two treatment groups at each assessment timepoint versus Baseline. Measurements of:
DXA Scan
Total bone mineral content
Bone mineral density at hips and lumbar spine Serum Osteocalcin 24-hour urinary excretion of deoxypyridinoline cross-links
12 monthly intervals until the age of 25yrs No
Secondary To assess the safety of GH treatment (IGF-I, Blood glucose, HbA1C, Blood pressure, Side effect questionnaire, Adverse events, Scheduled or unscheduled laboratory findings, Changes in concomitant medication) IGF-I Blood glucose HbA1C Blood pressure Side effect questionnaire Adverse events Scheduled or unscheduled laboratory findings Changes in concomitant medication 12 monthly intervals until the age of 25yrs No
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients